Literature DB >> 27116015

Confluence-dependent resistance to cisplatin in lung cancer cells is regulated by transforming growth factor-beta.

Saki Yokokura1, Nobuhiro Kanaji1, Akira Tadokoro1, Shigeyuki Yokokura1, Norimitsu Kadowaki1, Shuji Bandoh1.   

Abstract

PURPOSE OF THE STUDY: Confluence-dependent resistance (CDR) is a phenomenon in which the efficacy of anti-cancer agents decreases when cell density increases. CDR in lung cancer has never been reported. The purpose of this study is to investigate if CDR can occur in NSCLC cells and to find a role for transforming growth factor (TGF)-β as a mechanism of CDR.
MATERIALS AND METHODS: Non-small cell lung cancer (NSCLC) cell lines A549 and H2228 were exposed to cisplatin in a variety of cell density conditions. RNA interference targeting TGF-β receptor I was performed to silence the TGF-β pathway.
RESULTS: CDR to cisplatin was induced in NSCLC cells, whereas CDR to crizotinib, an inhibitor of activin receptor-like kinase, was not observed. During confluent conditions, the TGF-β1 concentration in the culture medium was the highest. Exogenous TGF-β1 inhibited cell proliferation and reduced sensitivity to cisplatin. Inhibition of the TGF-β pathway increased in terms of sensitivity to cisplatin at confluency.
CONCLUSIONS: CDR to cisplatin can occur in NSCLC cells, and the TGF-β pathway is associated with the regulation of CDR.

Entities:  

Keywords:  chemotherapy; cisplatin; crizotinib; confluence-dependent resistance; lung cancer; transforming growth factor-β

Mesh:

Substances:

Year:  2016        PMID: 27116015     DOI: 10.3109/01902148.2016.1172370

Source DB:  PubMed          Journal:  Exp Lung Res        ISSN: 0190-2148            Impact factor:   2.459


  4 in total

1.  The Association Between Heat-Shock Protein Polymorphisms and Prognosis in Lung Cancer Patients Treated With Platinum-Based Chemotherapy.

Authors:  Ting Zou; Jun-Yan Liu; Li She; Ji-Ye Yin; Xi Li; Xiang-Ping Li; Hong-Hao Zhou; Juan Chen; Zhao-Qian Liu
Journal:  Front Pharmacol       Date:  2020-07-21       Impact factor: 5.810

2.  Hepatocyte growth factor produced in lung fibroblasts enhances non-small cell lung cancer cell survival and tumor progression.

Authors:  Nobuhiro Kanaji; Masanao Yokohira; Yuko Nakano-Narusawa; Naoki Watanabe; Katsumi Imaida; Norimitsu Kadowaki; Shuji Bandoh
Journal:  Respir Res       Date:  2017-06-15

3.  Shenqi Fuzheng Injection Reverses Cisplatin Resistance through Mitofusin-2-Mediated Cell Cycle Arrest and Apoptosis in A549/DDP Cells.

Authors:  Ying Xiong; QiuYu Zhao; LiYan Gu; ChunYing Liu; Chun Wang
Journal:  Evid Based Complement Alternat Med       Date:  2018-10-16       Impact factor: 2.629

4.  Synergistic effect of a novel autophagy inhibitor and Quizartinib enhances cancer cell death.

Authors:  Amanda Tomie Ouchida; Yingbo Li; Jiefei Geng; Ayaz Najafov; Dimitry Ofengeim; Xiaoxiao Sun; Qiang Yu; Junying Yuan
Journal:  Cell Death Dis       Date:  2018-01-26       Impact factor: 8.469

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.